James Lim Final
San Francisco, Calif. (July 26, 2018) – Syapse announced today that James Lim has joined the company as Senior Vice President of Product Development. Lim brings more than 20 years of product and software expertise to his new role at Syapse, where he will lead development of Syapse’s precision medicine platform.
“Syapse has developed an extremely powerful platform that is making precision medicine a reality for more cancer patients,” said Lim. “The company has a laser focus on helping the entire precision medicine ecosystem deliver high-quality personalized care to every patient who needs it. I’m excited to join this stellar team and ensure our product continues to help our health system and pharmaceutical partners across the globe improve patient outcomes.”
An experienced executive who has successfully scaled innovative, first-to-market products, Lim will lead the effort to continuously evolve the Syapse platform to meet the needs of a growing base of health system customers and ecosystem partners in a rapidly changing field.
Before Syapse, Lim served as the Executive Vice President of Product and Engineering at Enlighted, where he built and delivered enterprise internet of things (IoT) software to some of the world’s largest healthcare, technology, and retail companies. Enlighted was acquired by Siemens in 2018. Lim was also Executive Vice President of Software at InvenSense, where he pioneered smart sensors and shipped billions of devices in the mobile, gaming, consumer, and IoT markets. He received his B.S. in electrical engineering from the University of Pennsylvania and his M.S. and Ph.D. in computer science engineering from Pennsylvania State University.
“James is the perfect fit for the Syapse team,” said Ken Tarkoff, CEO of Syapse. “His experience delivering and scaling innovative products across large enterprises is exactly what we need as we help more health systems and ecosystem partners scale their precision medicine efforts. We are excited to have him on board.”
He joins Syapse during a period of rapid growth for the company. Syapse recently formed the Syapse Precision Medicine Council—a group of clinical and business leaders from health systems dedicated to advancing precision oncology through sharing best practices. The company also expanded to Asia this year through a partnership with Seoul National University Hospital (SNUH), and launched partnerships with Roche and Medidata. Earlier this year, Syapse hired former Advisory Board executive Dennis Shin as Chief Commercial Officer and added Evolent Health CEO Frank Williams to its Board of Directors.
Syapse is on a mission to deliver the best care for every cancer patient through precision medicine. Our software platform, data sharing network, and industry partnerships enable healthcare providers to bring precision cancer care to every patient who needs it. By bringing together leading healthcare innovators into a unified ecosystem, we are working toward a future in which all cancer patients have access to the best personalized care, regardless of location or income. Our customers—including Intermountain Healthcare, Providence St. Joseph Health, Henry Ford Health System, Aurora Health Care, Catholic Health Initiatives and Dignity Health—manage one million active cancer cases at nearly 300 hospitals in 25 states. Headquartered in San Francisco, Syapse is backed by investors including Social Capital, Safeguard Scientifics, Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Merck Global Health Innovation Fund, Medidata Solutions, Roche Venture Fund, and Amgen Ventures.